Statement on signing of the Agriculture Improvement Act and the agency’s regulation of products containing cannabis and cannabis-derived compounds Statement on new steps to advance agency’s continued evaluation of potential regulatory pathways for cannabis-containing and cannabis-derived products FDA’s Cannabis Product Committee (CPC) develops and implements cross-Agency strategy and policy for the regulation of cannabis products.įDA Concludes that Existing Regulatory Frameworks for Foods and Supplements are Not Appropriate for Cannabidiol, Will Work with Congress on a New Way ForwardįDA Issues Response to Three Citizen Petitions related to CBD and Dietary SupplementsįDA Warns Companies for Illegally Selling Food and Beverage Products that Contain CBDįDA Warns Four Companies for Illegally Selling CBD Products Intended for Use in Food-Producing AnimalsįDA Issues Warning Letters to Companies Illegally Selling CBD and Delta-8 THC ProductsįDA Warns Companies Illegally Selling Over-the-Counter CBD Products for Pain ReliefįDA Warns Companies Illegally Selling CBD ProductsįDA Approves New Indication for Drug Containing an Active Ingredient Derived from Cannabis to Treat Seizures in Rare Genetic DiseaseįDA Warns Companies Illegally Selling CBD Products to Treat Medical Conditions, Opioid AddictionįDA Advances Work Related to Cannabidiol Products with Focus on Protecting Public Health, Providing Market ClarityįDA warns 15 companies for illegally selling various products containing cannabidiol as agency details safety concernsįDA, FTC warn company marketing unapproved cannabidiol products with unsubstantiated claims to treat teething and ear pain in infants, autism, ADHD, Parkinson’s and Alzheimer’s diseaseįDA warns company marketing unapproved cannabidiol products with unsubstantiated claims to treat cancer, Alzheimer's disease, opioid withdrawal, pain and pet anxietyįDA is Committed to Sound, Science-based Policy on CBD
0 Comments
Leave a Reply. |